Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis

News | Artificial Intelligence

Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

December 19, 2022 — Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has ...

December 19, 2022

Innovative approach can deliver high-fidelity cardiopulmonary exercise test results comparable to gold-standard testing with a wearable sensor during routine daily activities

News | Remote Monitoring

physIQ’s eVO2Max Demonstrates Breakout Ability to Estimate Cardiopulmonary Functional Capacity from Wearable Sensor Data During Daily Routine Activity

December 15, 2022 — physIQ announced a novel approach to estimating maximum oxygen utilization (VO2Max) using wearable ...

December 15, 2022

Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation, a leading research and advocacy organization, to find and more widely treat undiagnosed patients living with a common genetic condition that causes very high levels of unhealthy cholesterol, heightening the risk for heart attacks and strokes even at a young age.

News | STEMI

Emory Doctors and Family Heart Foundation Team Up to Help Patients with Dangerously High Cholesterol Caused by Genetic Condition

December 15, 2022 — Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation ...

December 15, 2022

From left, Qian Ma, PhD, and Yuqing Huo, MD, PhD. Photo courtesy of Michael Holahan, Augusta University

News | Heart Failure

New Target in the Fight Against Heart Disease

December 15, 2022 — Soon after cholesterol and fat start depositing on the lining of the blood vessels that supply your ...

December 15, 2022

Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS).

News | Stroke

Preventing Millions of Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding

December 14, 2022 — Verseon announced that the European Journal of Medicinal Chemistry has published a paper describing ...

December 14, 2022

Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.

News | Structural Heart

Edwards Announces One-year Data on Transfemoral Transcatheter Tricuspid Valve Replacement

December 13, 2022 — Edwards Lifesciences Corporation announced that one-year results on patients treated in the single ...

December 13, 2022

Image courtesy of Intermountain Healthcare

News | Cardiovascular Clinical Studies

Study Finds Patients Without Standard Modifiable Heart Risk Factors Are Common and More Likely to Fare Better After Heart Attack Than Patients with Known Factors

December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without ...

December 13, 2022

US-based Weill Cornell Medicine has initiated a new clinical project together with the Mwanza International Trials Unit located in the Lake Zone of Tanzania with the aim of exploring the burden of arrhythmia in adults with and without HIV.

News | Artificial Intelligence

Weill Cornell Medicine partners with Poland-based company Cardiomatics to investigate the relationship between HIV and heart rhythm disorders

December 12, 2022 — US-based Weill Cornell Medicine has initiated a new clinical project together with the Mwanza ...

December 12, 2022

Clinical abstract focuses on value of PURE EP’s and its groundbreaking High Frequency Algorithm (HFA) during pulmonary vein isolation

News | Cardiovascular Clinical Studies

BioSig’s PURE EP System Highlighted in the Journal of Atrial Fibrillation and Electrophysiology

December 9, 2022 — BioSig Technologies, Inc. an advanced digital signal processing technology company delivering ...

December 09, 2022

Dr. Rami Kahwash, director of Ohio State’s Heart and Vascular Research Organization and a professor of clinical medicine in the Ohio State College of Medicine.

News | Cardiovascular Clinical Studies

Ohio State First in World to Participate in Trial Confirming Efficacy of Novel Heart Failure Treatment

December 9, 2022 — The Ohio State University Wexner Medical Center is first in the world to randomize a patient in a ...

December 09, 2022

News | Cardiovascular Clinical Studies

Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy

December 9, 2022 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies ...

December 09, 2022

Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint

News | Cardiovascular Clinical Studies

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL (bempedoic acid) Meets Primary Endpoint

December 8, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regim ...

December 08, 2022

Allogeneic CardiALLO therapy for heart failure to complement autologous cell therapy currently enrolling in Phase III CardiAMP Heart Failure clinical trial

News | Heart Failure

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

December 7, 2022 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

December 07, 2022

Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2TM Aortic Valve System.

News | Structural Heart

Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success and Safety of the ACURATE neo2 Aortic Valve System

December 2, 2022 — Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market ...

December 02, 2022

Transverse heart sections from wild type mice (WT) and transgenic mice overexpressing beta-3 adrenergic receptor in cardiomyocytes (c-hB3tg) after 3 months of aortic stenosis (transaortic constriction, TAC) or control (sham). Hypertrophy after TAC was less severe in the transgenic mice. Courtesy of CNIC

News | Heart Failure

A New Therapeutic Target for the Prevention of Heart Failure Due to Aortic Stenosis

December 1, 2022 — Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified a new ...

December 01, 2022